Phathom Pharmaceuticals (NASDAQ:PHAT) has received an average broker rating score of 1.33 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.
Brokerages have set a 1 year consensus price objective of $36.00 for the company and are anticipating that the company will post ($0.82) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Phathom Pharmaceuticals an industry rank of 56 out of 255 based on the ratings given to related companies.
Several brokerages have recently commented on PHAT. Evercore ISI began coverage on Phathom Pharmaceuticals in a report on Wednesday, November 27th. They set an “outperform” rating on the stock. Goldman Sachs Group began coverage on Phathom Pharmaceuticals in a report on Wednesday, November 27th. They set a “neutral” rating and a $32.00 target price on the stock. Needham & Company LLC began coverage on Phathom Pharmaceuticals in a report on Wednesday, November 27th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Jefferies Financial Group began coverage on Phathom Pharmaceuticals in a report on Wednesday, November 27th. They set a “buy” rating and a $32.00 target price on the stock.
In other news, major shareholder Life Sciences Ix L.P. Frazier purchased 1,052,631 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were acquired at an average price of $23.56 per share, with a total value of $24,799,986.36.
Shares of PHAT stock traded up $1.00 during trading hours on Friday, hitting $22.25. 111,417 shares of the company’s stock were exchanged, compared to its average volume of 101,693. Phathom Pharmaceuticals has a 52 week low of $20.26 and a 52 week high of $28.51.
Phathom Pharmaceuticals Company Profile
Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related diseases.
Further Reading: What are the Benefits of Index Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.